Get the Stockscreener App
48.63
0.56%
0.27
Collegium Pharmaceutical Inc stock is traded at $48.63, with a volume of 369.38K.
It is up +0.56% in the last 24 hours and up +2.70% over the past month.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
See More
Previous Close:
$48.36
Open:
$48.525
24h Volume:
369.38K
Relative Volume:
0.80
Market Cap:
$1.54B
Revenue:
$566.77M
Net Income/Loss:
$48.16M
P/E Ratio:
40.87
EPS:
1.19
Net Cash Flow:
$274.29M
1W Performance:
+1.50%
1M Performance:
+2.70%
6M Performance:
+64.29%
1Y Performance:
+61.62%
1-Day Range:
$47.85
$48.97
1-Week Range:
$46.15
$49.16
52-Week Range:
$23.23
$49.16
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Name
Collegium Pharmaceutical Inc
Sector
Phone
781-713-3699
Address
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
48.63 | 1.53B | 566.77M | 48.16M | 274.29M | 1.19 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jan-10-25 | Upgrade | Needham | Hold → Buy |
| Jul-30-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-07-24 | Upgrade | Jefferies | Hold → Buy |
| May-10-24 | Downgrade | Needham | Buy → Hold |
| May-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-25-23 | Reiterated | Needham | Buy |
| May-02-23 | Resumed | Jefferies | Buy |
| Aug-08-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-15-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-06-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Jul-14-20 | Initiated | BWS Financial | Sell |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Feb-19-20 | Resumed | Jefferies | Buy |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-03-19 | Resumed | H.C. Wainwright | Buy |
| Apr-12-19 | Resumed | Janney | Buy |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Jan-16-19 | Reiterated | Needham | Buy |
| Mar-08-18 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-18 | Reiterated | Needham | Buy |
| Dec-05-17 | Reiterated | Needham | Buy |
| Sep-11-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Reiterated | Needham | Buy |
| Sep-13-16 | Initiated | Gabelli & Co | Buy |
| Jun-01-15 | Initiated | Jefferies | Buy |
| Jun-01-15 | Initiated | Needham | Buy |
| Jun-01-15 | Initiated | Piper Jaffray | Overweight |
View All
Collegium Pharmaceutical Inc Stock (COLL) Latest News
Collegium Pharmaceutical Inc 354 Stock Analysis and ForecastMarket Volatility Update & Exceptional Return Growth - earlytimes.in
Insider Selling: Collegium Pharmaceutical (NASDAQ:COLL) EVP Sells 17,600 Shares of Stock - MarketBeat
Collegium Pharmaceutical stock hits all-time high at 49.11 USD By Investing.com - Investing.com Canada
Collegium pharmaceutical EVP Dreyer sells $847k in stock - Investing.com India
Collegium pharmaceutical EVP Dreyer sells $847k in stock By Investing.com - Investing.com Australia
Collegium Pharmaceutical Insider Sold Shares Worth $847,855, According to a Recent SEC Filing - marketscreener.com
Collegium Pharmaceutical (NASDAQ:COLL) Now Covered by Analysts at Barclays - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Director Rita Balice-Gordon Sells 3,650 Shares - MarketBeat
Does Zacks’ Value Spotlight on Collegium (COLL) Reframe Its Cash-Flow Story for Investors? - simplywall.st
Barclays Initiates Collegium Pharmaceutical at Overweight With $58 Price Target - marketscreener.com
Collegium Pharmaceutical (NASDAQ:COLL) Hits New 12-Month HighWhat's Next? - MarketBeat
Collegium (NASDAQ:COLL) Nasdaq Biggest Companies Pharma Activity - Kalkine Media
Collegium Pharmaceutical (COLL): Revisiting Valuation After Fresh Coverage and Ongoing Earnings Outperformance - Yahoo Finance
Collegium Pharmaceutical (COLL): Assessing Valuation After Earnings Beats, Strong Zacks Rating and Value Investor Interest - simplywall.st
Can Collegium Pharmaceutical Inc. stock withstand economic slowdown2025 Sector Review & Safe Investment Capital Preservation Plans - Newser
Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run? - sharewise.com
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? - sharewise.com
Can Collegium Pharmaceutical Inc. (354) stock hit consensus price targetsJuly 2025 News Drivers & Consistent Growth Stock Picks - Newser
What RSI levels show for Collegium Pharmaceutical Inc. (354) stockEarnings Trend Report & Weekly High Return Forecasts - Newser
How Collegium Pharmaceutical Inc. stock responds to policy changesWeekly Trade Recap & Real-Time Stock Movement Alerts - Newser
Collegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month HighStill a Buy? - MarketBeat
Will Collegium Pharmaceutical Inc. (354) stock justify high valuationQuarterly Earnings Summary & Stepwise Entry/Exit Trade Alerts - Newser
Will Collegium Pharmaceutical Inc. (354) stock benefit from commodity supercycle2025 Investor Takeaways & Weekly Chart Analysis and Guides - Newser
Will Collegium Pharmaceutical Inc. (354) stock sustain uptrend momentum2025 Momentum Check & Free Expert Verified Stock Movement Alerts - Newser
Collegium Pharmaceutical stock hits all-time high at 48.19 USD By Investing.com - Investing.com Australia
Collegium Pharmaceutical stock hits all-time high at 48.19 USD - Investing.com
Loomis Sayles & Co. L P Increases Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Will Collegium Pharmaceutical Inc. (354) stock hit analyst forecastsWeekly Stock Report & AI Enhanced Trade Execution Alerts - Newser
Can Collegium Pharmaceutical Inc. (354) stock withstand sector downturnsPortfolio Risk Report & AI Driven Price Forecasts - Newser
Why Collegium Pharmaceutical Inc. (354) stock is a strong analyst pickTrade Volume Report & Real-Time Volume Surge Alerts - Newser
Ballast Asset Management LP Makes New Investment in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Geode Capital Management LLC Increases Stock Holdings in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium Pharmaceutical, Inc. (COLL) Stock Forecasts - Yahoo Finance
Collegium Pharmaceutical Reports Record Q3 2025 Results - MSN
Collegium Pharmaceutical (COLL): Exploring Valuation After Recent Share Price Surge - simplywall.st
Precision Trading with Collegium Pharmaceutical Inc. (COLL) Risk Zones - news.stocktradersdaily.com
Is Collegium Pharmaceutical Inc 354 a good long term investmentEarnings Per Share Trends & Low Risk Portfolio Growth - earlytimes.in
Why Investors Shouldn't Be Surprised By Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 26% Share Price Surge - 富途牛牛
Free cash flow per share of Collegium Pharmaceutical, Inc. – TRADEGATE:354 - TradingView
Collegium Pharmaceutical collaborates with Paris Hilton - MSN
Brandywine Global Investment Management LLC Increases Stake in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Why 2025 is a Dynamic and Transformative Year for Collegium - MSN
1 Small-Cap Stock with Exciting Potential and 2 We Avoid - The Globe and Mail
Has Analyst Spotlight on COLL Revealed a Turning Point in Its Competitive Advantage? - simplywall.st
Collegium Pharmaceutical Inc Stock (COLL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):